Skip to main content
. 2023 Jan 30;19(1):2169531. doi: 10.1080/21645515.2023.2169531

Figure 14.

Figure 14.

Ranking diagram of PD-L1-positive and -negative subgroups. (a) Ranking diagram of OS of PD-L1-positive NSCLC patients; (b) Ranking diagram of PFS of PD-L1-positive NSCLC patients; (c) Ranking diagram of OS of PD-L1-negative NSCLC patients; (d) Ranking diagram of PFS of PD-L1-negative NSCLC patients Atez: atezolizumab; Chem: chemotherapy; Nivo: nivolumab; Ipil: ipilimumab.